Wednesday, December 14, 2016

BRIEF-European Commission grants Intercept'S Ocaliva marketing authorization

* European Commission grants Intercept'S

Ocaliva(obeticholic acid) marketing authorization for the

treatment of primary biliary cholangitis

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)